1.Machine-learning-based models assist the prediction of pulmonary embolism in autoimmune diseases: A retrospective, multicenter study
Ziwei HU ; Yangyang HU ; Shuoqi ZHANG ; Li DONG ; Xiaoqi CHEN ; Huiqin YANG ; Linchong SU ; Xiaoqiang HOU ; Xia HUANG ; Xiaolan SHEN ; Cong YE ; Wei TU ; Yu CHEN ; Yuxue CHEN ; Shaozhe CAI ; Jixin ZHONG ; Lingli DONG
Chinese Medical Journal 2024;137(15):1811-1822
		                        		
		                        			
		                        			Background::Pulmonary embolism (PE) is a severe and acute cardiovascular syndrome with high mortality among patients with autoimmune inflammatory rheumatic diseases (AIIRDs). Accurate prediction and timely intervention play a pivotal role in enhancing survival rates. However, there is a notable scarcity of practical early prediction and risk assessment systems of PE in patients with AIIRD.Methods::In the training cohort, 60 AIIRD with PE cases and 180 age-, gender-, and disease-matched AIIRD non-PE cases were identified from 7254 AIIRD cases in Tongji Hospital from 2014 to 2022. Univariable logistic regression (LR) and least absolute shrinkage and selection operator (LASSO) were used to select the clinical features for further training with machine learning (ML) methods, including random forest (RF), support vector machines (SVM), neural network (NN), logistic regression (LR), gradient boosted decision tree (GBDT), classification and regression trees (CART), and C5.0 models. The performances of these models were subsequently validated using a multicenter validation cohort.Results::In the training cohort, 24 and 13 clinical features were selected by univariable LR and LASSO strategies, respectively. The five ML models (RF, SVM, NN, LR, and GBDT) showed promising performances, with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.962-1.000 in the training cohort and 0.969-0.999 in the validation cohort. CART and C5.0 models achieved AUCs of 0.850 and 0.932, respectively, in the training cohort. Using D-dimer as a pre-screening index, the refined C5.0 model achieved an AUC exceeding 0.948 in the training cohort and an AUC above 0.925 in the validation cohort. These results markedly outperformed the use of D-dimer levels alone.Conclusion::ML-based models are proven to be precise for predicting the onset of PE in patients with AIIRD exhibiting clinical suspicion of PE.Trial Registration::Chictr.org.cn: ChiCTR2200059599.
		                        		
		                        		
		                        		
		                        	
2.COVID-19 in the immunocompromised population: data from renal allograft recipients throughout full cycle of the outbreak in Hubei province, China.
Weijie ZHANG ; Fei HAN ; Xiongfei WU ; Zhendi WANG ; Yanfeng WANG ; Xiaojun GUO ; Song CHEN ; Tao QIU ; Heng LI ; Yafang TU ; Zibiao ZHONG ; Jiannan HE ; Bin LIU ; Hui ZHANG ; Zhitao CAI ; Long ZHANG ; Xia LU ; Lan ZHU ; Dong CHEN ; Jiangqiao ZHOU ; Qiquan SUN ; Zhishui CHEN
Chinese Medical Journal 2021;135(2):228-230
3.Kinetic Characteristics of Neutralizing Antibody Responses Vary among Patients with COVID-19.
Ling Hua LI ; Hong Wei TU ; Dan LIANG ; Chun Yan WEN ; An An LI ; Wei Yin LIN ; Ke Qi HU ; Wen Shan HONG ; Yue Ping LI ; Juan SU ; San Tao ZHAO ; Wei LI ; Run Yu YUAN ; Ping Ping ZHOU ; Feng Yu HU ; Xiao Ping TANG ; Chang Wen KE ; Bi Xia KE ; Wei Ping CAI
Biomedical and Environmental Sciences 2021;34(12):976-983
		                        		
		                        			Objective:
		                        			The coronavirus disease 2019 (COVID-19) pandemic continues to present a major challenge to public health. Vaccine development requires an understanding of the kinetics of neutralizing antibody (NAb) responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
		                        		
		                        			Methods:
		                        			In total, 605 serum samples from 125 COVID-19 patients (from January 1 to March 14, 2020) varying in age, sex, severity of symptoms, and presence of underlying diseases were collected, and antibody titers were measured using a micro-neutralization assay with wild-type SARS-CoV-2.
		                        		
		                        			Results:
		                        			NAbs were detectable approximately 10 days post-onset (dpo) of symptoms and peaked at approximately 20 dpo. The NAb levels were slightly higher in young males and severe cases, while no significant difference was observed for the other classifications. In follow-up cases, the NAb titer had increased or stabilized in 18 cases, whereas it had decreased in 26 cases, and in one case NAbs were undetectable at the end of our observation. Although a decreasing trend in NAb titer was observed in many cases, the NAb level was generally still protective.
		                        		
		                        			Conclusion
		                        			We demonstrated that NAb levels vary among all categories of COVID-19 patients. Long-term studies are needed to determine the longevity and protective efficiency of NAbs induced by SARS-CoV-2.
		                        		
		                        		
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Aged, 80 and over
		                        			;
		                        		
		                        			Antibodies, Neutralizing/immunology*
		                        			;
		                        		
		                        			Antibodies, Viral/immunology*
		                        			;
		                        		
		                        			COVID-19/immunology*
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Kinetics
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Neutralization Tests
		                        			;
		                        		
		                        			SARS-CoV-2
		                        			
		                        		
		                        	
4.A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis.
Lin CAI ; Gen-Hui CHEN ; Qian-Jin LU ; Min ZHENG ; Yu-Zhen LI ; Jin CHEN ; Jie ZHENG ; Fu-Ren ZHANG ; Jian-Bin YU ; Sen YANG ; Fu-Qiu LI ; Sheng-Xiang XIAO ; Qiu-Ning SUN ; Jin-Hua XU ; Xing-Hua GAO ; Hong FANG ; Tian-Wen GAO ; Fei HAO ; Quan-Zhong LIU ; Ya-Ting TU ; Ruo-Yu LI ; Bao-Xi WANG ; Dan-Qi DENG ; Qing-Shan ZHENG ; Hong-Xia LIU ; Jian-Zhong ZHANG
Chinese Medical Journal 2020;133(24):2905-2909
		                        		
		                        			BACKGROUND:
		                        			Benvitimod cream, a novel synthetic small molecule, was effective in treating mild-to-moderate plaque psoriasis. We conducted a phase III clinical trial to assess the efficacy and safety of benvitimod cream in patients with mild-to-moderate plaque psoriasis.
		                        		
		                        			METHODS:
		                        			We randomly assigned 686 patients (2:1:1) to receive 1% benvitimod cream, 0.005% calcipotriol ointment or placebo twice a day for 12 weeks. The primary efficacy end points were the percentage of patients with a 75% or greater reduction from baseline in the psoriasis area and severity index (PASI 75) score and with a score of 0 or 1 in static physician's global assessment (sPGA) at week 12.
		                        		
		                        			RESULTS:
		                        			The results showed that 50.4% of patients in the benvitimod group achieved PASI 75, which was significantly higher than that in the calcipotriol (38.5%, P < 0.05) and placebo (13.9%, P < 0.05) groups. The proportion of patients achieving an sPGA score 0 or 1 was 66.3% in the benvitimod group and 63.9% in the calcipotriol group, which were both significantly higher than that in the placebo group (34%, P < 0.05). In the long-term follow-up study, 50.8% of patients experienced recurrence. After retreatment with 1% benvitimod, 73.3% of patients achieved an sPGA score of 0 or 1 again at week 52. Adverse events included application site irritation, follicular papules, and contact dermatitis. No systemic adverse reactions were reported.
		                        		
		                        			CONCLUSION:
		                        			During this 12-week study, benvitimod cream was demonstrated with high effectiveness and safety in patients with mild-to-moderate plaque psoriasis.
		                        		
		                        			TRIAL REGISTRATION
		                        			Chinese Clinical Trial Registry (ChiCTR), ChiCTR-TRC-13003259; http://www.chictr.org.cn/showprojen.aspx?proj=6300.
		                        		
		                        		
		                        		
		                        			Double-Blind Method
		                        			;
		                        		
		                        			Follow-Up Studies
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Ointments
		                        			;
		                        		
		                        			Psoriasis/drug therapy*
		                        			;
		                        		
		                        			Resorcinols
		                        			;
		                        		
		                        			Severity of Illness Index
		                        			;
		                        		
		                        			Stilbenes
		                        			;
		                        		
		                        			Treatment Outcome
		                        			
		                        		
		                        	
5.in vitro metabolism of daphnetin in rat liver S9 fractions
Si-cheng LIANG ; Guang-bo GE ; Yang-liu XIA ; Xiao-yi QI ; Ao-xue WANG ; Cai-xia TU ; Ling YANG
Acta Pharmaceutica Sinica 2017;52(2):291-295
		                        		
		                        			
		                        			 Daphnetin is quickly eliminated in rats after dosing, but the mechanism remains unclear. This study was aimed to investigate the in vitro metabolism of daphnetin using rat liver S9 fractions (RLS9). The metabolites formed in RLS9 were identified and the kinetic parameters for different metabolic pathways were determined. HPLC-DAD-MS analysis showed that daphnetin was biotransformed to six metabolites, which were identified as 7 or 8 mono-glucuronide and mono-sulfate, 8-methylate, and 7-suflo-8-methylate. Methylation and glucuronidation of daphnetin exhibited the Michaelis-Menten kinetic characteristics, whereas the substrate inhibition kinetic and the two-site kinetic were observed for 8-sulfate and 7-sulfate formations. Of the 3 conjugation pathways, the intrinsic clearance rate for sulfation was highest, followed by methylation and glucuronidation. By in vitro-in vivo extrapolation of the kinetic data measured in RLS9, the hepatic clearance were estimated to be 54.9 mL·min-1·kg-1 which is comparable to the system clearance (58.5 mL·min-1·kg-1) observed in rats. In conclusions, the liver might be the main site for daphnetin metabolism in rats. Sulfation, methylation and glucuronidation are important pathways of the hepatic metabolism of daphnetin in rats. 
		                        		
		                        		
		                        		
		                        	
6.Opacity proteins of neisseria gonorrhoeae in lipooligosaccharide mutants lost ability to interact with neutrophil-restricted CEACAM3 (CD66d).
Song ZHANG ; Ya-Ting TU ; Hua-Hua CAI ; Hong-Hui DING ; Qiao LI ; Ying-Xia HE ; Xin-Xin LIU ; Xin WANG ; Feng HU ; Tie CHEN ; Hong-Xiang CHEN
Journal of Huazhong University of Science and Technology (Medical Sciences) 2016;36(3):344-349
		                        		
		                        			
		                        			Lipooligosacharide (LOS) of Neisseria gonorrhoeae (gonococci, GC) is involved in the interaction of GC with host cells. Deletion of the alpha-oligosaccharide (alpha-OS) moiety of LOS (lgtF mutant) significantly impairs invasion of GC into epithelial cell lines. GC opacity (Opa) proteins, such as OpaI, mediate phagocytosis and stimulate chemiluminescence responses in neutrophils in part through interaction with members of the carcinoembryonic antigen (CEA) family, which includes CEACAM3 (CD66d), a human neutrophil specific receptor for phagocytosis of bacteria. In the present work, we examined the effects of OpaI-expressing lgtF mutant on phagocytosis by HeLa-CEACAM3 cells and chemiluminescence responses in neutrophils. The results showed that lgtF mutant even expressing OpaI completely lost the ability to promote either phagocytosis mediated by CEACAM3 interaction in HeLa cells or chemiluminescence responses in neutrophils. These data indicated that Opa proteins in the lgtF mutant, which might result from the conformational change, cannot be functional.
		                        		
		                        		
		                        		
		                        			Antigens, Bacterial
		                        			;
		                        		
		                        			chemistry
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			immunology
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			Carbohydrate Sequence
		                        			;
		                        		
		                        			Carcinoembryonic Antigen
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			immunology
		                        			;
		                        		
		                        			Gene Expression Regulation
		                        			;
		                        		
		                        			HeLa Cells
		                        			;
		                        		
		                        			Host-Pathogen Interactions
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Lipopolysaccharides
		                        			;
		                        		
		                        			chemistry
		                        			;
		                        		
		                        			immunology
		                        			;
		                        		
		                        			Luminescent Measurements
		                        			;
		                        		
		                        			Mutation
		                        			;
		                        		
		                        			Neisseria gonorrhoeae
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			pathogenicity
		                        			;
		                        		
		                        			Neutrophils
		                        			;
		                        		
		                        			immunology
		                        			;
		                        		
		                        			microbiology
		                        			;
		                        		
		                        			Phagocytosis
		                        			
		                        		
		                        	
7.Clinical Features of Adult/Adolescent Atopic Dermatitis and Chinese Criteria for Atopic Dermatitis.
Ping LIU ; Yan ZHAO ; Zhang-Lei MU ; Qian-Jin LU ; Li ZHANG ; Xu YAO ; Min ZHENG ; Yi-Wen TANG ; Xin-Xiang LU ; Xiu-Juan XIA ; You-Kun LIN ; Yu-Zhen LI ; Cai-Xia TU ; Zhi-Rong YAO ; Jin-Hua XU ; Wei LI ; Wei LAI ; Hui-Min YANG ; Hong-Fu XIE ; Xiu-Ping HAN ; Zhi-Qiang XIE ; Xiang NONG ; Zai-Pei GUO ; Dan-Qi DENG ; Tong-Xin SHI ; Jian-Zhong ZHANG
Chinese Medical Journal 2016;129(7):757-762
BACKGROUNDAtopic dermatitis (AD) is an inflammatory skin disease characterized by chronic recurrent dermatitis with profound itching. Most patients have personal and/or family history of atopic diseases. Several criteria have been proposed for the diagnosis of AD. Although the clinical features of childhood AD have been widely studied, there has been less large-scale study on adult/adolescent AD. The aim of this study was to investigate the clinical features of adult/adolescent patients with chronic symmetrical eczema/AD and to propose Chinese diagnostic criteria for adult/adolescent AD.
METHODSA hospital-based study was performed. Forty-two dermatological centers participated in this study. Adult and adolescent patients (12 years and over) with chronic symmetrical eczema or AD were included in this study. Questionnaires were completed by both patients and investigators. The valid questionnaires were analyzed using EpiData 3.1 and SPSS 17.0 software.
RESULTSA total of 2662 valid questionnaires were collected (1369 male and 1293 female). Of all 2662 patients, 2062 (77.5%) patients had the disease after 12 years old, while only 600 (22.5%) patients had the disease before 12 years old, suggesting late-onset eczema/AD is common. Two thousand one hundred and thirty-nine (80.4%) patients had the disease for more than 6 months. One thousand one hundred and forty-four (43.0%) patients had a personal and/or family history of atopic diseases. One thousand five hundred and forty-eight (58.2%) patients had an elevated total serum IgE and/or eosinophilia and/or positive allergen-specific IgE. Based on these clinical and laboratory features, we proposed Chinese criteria for adult/adolescent AD. Of all 2662 patients, 60.3% were satisfied with our criteria, while only 48.2% satisfied with Hanifin Rajka criteria and 32.7% satisfied with Williams criteria, suggesting a good sensitivity of our criteria in adult/adolescent AD patients.
CONCLUSIONLate-onset of eczema or AD is common. The clinical manifestations of AD are heterogeneous. We have proposed Chinese diagnostic criteria for adolescent and adult AD, which are simple and sensitive for diagnosis of adult/adolescent AD.
Adolescent ; Adult ; Dermatitis, Atopic ; diagnosis ; immunology ; Eczema ; diagnosis ; Female ; Humans ; Immunoglobulin E ; blood ; Male ; Middle Aged ; Retrospective Studies ; Surveys and Questionnaires
8. New drugs for gont: Research advances
Journal of International Pharmaceutical Research 2016;43(5):858-862
		                        		
		                        			
		                        			 Gout is a common disease in the elderly men. The prevalence rate of gout is rising worldwide in recent years, and gout has become a serious metabolic disease threatening human health. Moreover, gout is also closely related to incidence of many diseases and symptoms such as hypertension, hyperlipidemia, atherosclerosis, obesity and insulin resistance. Recently, investigation and development of new drugs have attracted increasing attention. This paper summarizes the research advances in new agents for treatment of gout, including the uric acid reduction drugs that target the key enzymes of purine metabolism, the drugs which target the renal tubular urate transporters to lower the uric acid level, the dual inhibitors of xanthine oxidoreductase(XOR) and renal tubular urate transporters, and the uricase. 
		                        		
		                        		
		                        		
		                        	
9.Status Analysis and Countermeasures for Service of TCM Non-communicable Chronic
Qiu-jie CAI ; Juan ZHANG ; Hai-xia DANG ; Ya TU ; Zhe LI
Chinese Journal of Information on Traditional Chinese Medicine 2015;(2):4-7
		                        		
		                        			
		                        			Objective To provide new ideas for establishment of prevention and control strategy for non-communicable chronic disease (NCD) that are suitable for Chinese people. Methods Sampling survey of patients with chronic disease from 14 provinces combined with literature study and researches on national statistical data were conducted to investigate the application situation and problems of traditional Chinese medicine in the prevention and control of NCD. Results Status of utilization and satisfaction of traditional Chinese medicine in the prevention and control of NCD has developed well. The main problems in the promotion and application of TCM lie in insufficient investment, lagging behind of construction of prevention and control system, insufficient professionals and ineffective heritance of practical technique. Conclusion In order to tackle these problems, relevant laws and regulations should be implemented;information management system with TCM features should be improved;construction of diversified technological innovation system should be reinforced, practical and strong technology should be promoted;construction of TCM prevention and control system for chronic diseases should be perfected.
		                        		
		                        		
		                        		
		                        	
10.Expression of suppressor of cytokine signaling-3 and caspase-3 in endometriosis and their correlation.
Wei-dong WEI ; Fei RUAN ; Fei-xia TU ; Cai-yun ZHOU ; Jun LIN
Chinese Journal of Pathology 2013;42(8):515-518
OBJECTIVETo investigate the expression of suppressor of cytokine signaling(SOCS)-3 and caspase-3 and their correlative significance in endometriosis.
METHODSImmunohistochemical EnVision method was used to detect the SOCS-3 and caspase-3 protein expression in ectopic and eutopic endometrium (n = 32) of patients with endometriosis, as well as normal endometrium (n = 30) of women without endometriosis.
RESULTSSOCS-3 and caspase-3 proteins were expressed in all three groups and not affected by the menstrual cycles. The expression of SOCS-3 in ectopic endometrium (5.54 ± 2.12) was significantly lower than that in eutopic (7.39 ± 1.09, P = 0.001) and control group (7.48 ± 1.26, P < 0.01), but without difference between the eutopic and control group (P = 0.756). SOCS-3 expression in ectopic and eutopic endometrium was significantly lower in III/IV stages than that in I/II stages of endometriosis (P < 0.05). Significantly lower expression of caspase-3 protein was found in ectopic (3.20 ± 1.24) and eutopic endometrium (3.88 ± 1.93) as compared with the control group (6.49 ± 1.85, P < 0.01), however ectopic and eutopic endometrium showed no significant difference (t = 1.66, P = 0.10). There was no significant difference of the expression of caspase-3 in ectopic and eutopic endometrium at different disease stages (P > 0.05). Positive correlation was found between the expression of SOCS-3 and caspase-3 proteins in ectopic endometrium (r = 0.655, P < 0.01).
CONCLUSIONSOCS-3 may be involved in the development of endometriosis through inhibition of apoptosis of ectopic endometrial cells.
Adult ; Caspase 3 ; metabolism ; Endometriosis ; metabolism ; pathology ; Endometrium ; metabolism ; pathology ; Female ; Humans ; Immunohistochemistry ; Menstrual Cycle ; Middle Aged ; Suppressor of Cytokine Signaling 3 Protein ; Suppressor of Cytokine Signaling Proteins ; metabolism ; Uterine Diseases ; metabolism ; pathology ; Young Adult
            
Result Analysis
Print
Save
E-mail